<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-124775</identifier>
<setSpec>0211-6995</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Prevalence of anaemia and its clinical management in patients with stages 3-5 chronic kidney disease not on dialysis in Catalonia: MICENAS I study</dc:title>
<dc:description xml:lang="en">Introduction: Anaemia is a common complication of chronic kidney disease (CKD). The aim of this study was to determine the prevalence and clinical management of anaemia in patients with stages 3-5 CKD not on dialysis treated in outpatient Nephrology clinics (OC) in Catalonia. Methods: Epidemiological, cross-sectional cohort, multicentre study under routine clinical practice conditions. Data collection by electronic data collection log-book (e-DCL) including personal information and data related to anaemia (haemoglobin, iron status, treatment with erythropoiesis-stimulating agents [ESA] and other anaemia treatments). Anaemia was defined as haemoglobin levels &lt;13.5g/dL in males or &lt;12g/dL in females or patients who receive treatment with ESA. Results: We included 504 patients (56.4% male, mean age of 67.8±15.5 years): 61.5% had stage 3 CKD, 30.2% stage 4 and 8.3% stage 5. The main causes of CKD were vascular and diabetic nephropathy. The prevalence of anaemia was 58.5% (n=295), however, only 14.9% of patients had haemoglobin levels &lt;11g/dL. Mean haemoglobin levels decreased and ESA treatment was more common as CKD progressed, but no significant differences were observed regarding the prescription of iron, according to CKD stages. ESA and intervals most frequently prescribed were darbepoetin alfa with a median dose of 40&amp;#956;g/biweekly, followed by C.E.R.A. with a median dose of 75&amp;#956;g/month and epoetin beta with a median dose of 5,000IU/week. Among the patients with anaemia (n=295), 36.3% (n=107) had iron deficiency and only 53.3% of these patients were treated with iron supplements. Conclusions: This study demonstrates the high prevalence of anaemia, which increases as the disease progresses and its good control in a CKD patient population treated in Nephrology outpatient clinics in Catalonia. This control is achieved with moderate doses of ESA and iron supplements prescribed in more than 50% of anaemic CKD patients (AU)</dc:description>
<dc:creator>Investigadores del estudio MICENAS I</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Introducción: La anemia es una complicación frecuente de la enfermedad renal crónica (ERC). El objetivo de este estudio fue conocer la prevalencia de anemia en pacientes con ERC estadios 3-5 no en diálisis atendidos en consultas externas (CCEE) de Nefrología en Cataluña y su manejo clínico. Metodología: Estudio epidemiológico, de cohorte transversal, multicéntrico, en condiciones de práctica clínica habitual. Recogida de datos mediante un e-CRD que incluía datos de filiación y aquellos relacionados con la anemia (hemoglobina, estatus férrico, tratamiento con agentes estimuladores de la eritropoyesis [AEE] y con otros coadyuvantes). Se definió anemia como unos niveles de hemoglobina &lt; 13,5 g/dl en varones o &lt; 12 g/dl en mujeres o pacientes que recibieran tratamiento con AEE. Resultados: Se incluyeron 504 pacientes (56,4 % varones, edad media de 67,8 ± 15,5 años): 61,5 % presentaban ERC estadio 3, 30,2 % estadio 4 y 8,3 % estadio 5. Las principales causas de ERC fueron la vascular y la nefropatía diabética. La prevalencia de anemia fue del 58,5 % (n = 295); sin embargo, solo un 14,9 % de los pacientes tenían niveles de hemoglobina &lt; 11 g/dl. Los niveles medios de hemoglobina disminuían y el tratamiento con AEE era más frecuente a medida que progresaba la ERC, pero no se observaron diferencias significativas respecto a la prescripción de hierro, según (..) (AU)</dc:description>
<dc:source>Nefrologia;34(2): 189-198, mar.-abr. 2014. ilus, tab</dc:source>
<dc:identifier>ibc-124775</dc:identifier>
<dc:title xml:lang="es">Prevalencia de anemia y su manejo clínico en la enfermedad renal crónica estadios 3-5 no en diálisis en Cataluña: estudio MICENAS I</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d7668^s22073</dc:subject>
<dc:subject>^d755^s22080</dc:subject>
<dc:subject>^d50497^s22012</dc:subject>
<dc:subject>^d5009^s22021</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d32369^s22057</dc:subject>
<dc:subject>^d16595^s22057</dc:subject>
<dc:subject>^d32285</dc:subject>
<dc:subject>^d32959^s22080</dc:subject>
<dc:type>article</dc:type>
<dc:date>201404</dc:date>
</metadata>
</record>
</ibecs-document>
